These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 3278833)

  • 41. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections.
    Betrosian AP; Douzinas EE
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1099-112. PubMed ID: 19621991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Betalactam antibiotics combined with bectalactamases inhibitors. Amoxicillin-sulbactam].
    Barcelona L; Marín M; Stamboulian D
    Medicina (B Aires); 2008; 68(1):65-74. PubMed ID: 18416324
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Friedel HA; Campoli-Richards DM; Goa KL
    Drugs; 1989 Apr; 37(4):491-522. PubMed ID: 2661196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rational antibiotic therapy and the position of ampicillin/sulbactam.
    Lode HM
    Int J Antimicrob Agents; 2008 Jul; 32(1):10-28. PubMed ID: 18539004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sulbactam-containing beta-lactamase inhibitor combinations.
    Akova M
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():185-8. PubMed ID: 18154545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination.
    Stein GE; Gurwith MJ
    Clin Pharm; 1984; 3(6):591-9. PubMed ID: 6391783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pharmacokinetics of sultamicillin.
    Lode H; Hampel B; Bruckner G; Koeppe P
    APMIS Suppl; 1989; 5():17-22. PubMed ID: 2660866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical trials of extended spectrum penicillin/beta-lactamase inhibitors in the treatment of intra-abdominal infections. European and North American experience.
    Wilson SE; Nord CE
    Am J Surg; 1995 May; 169(5A Suppl):21S-26S. PubMed ID: 7755164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beta-lactamase inhibitors from laboratory to clinic.
    Bush K
    Clin Microbiol Rev; 1988 Jan; 1(1):109-23. PubMed ID: 3060240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic properties of beta-lactamase inhibitors.
    de la Pena A; Derendorf H
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):63-75. PubMed ID: 10082170
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination.
    Benson JM; Nahata MC
    Drug Intell Clin Pharm; 1988; 22(7-8):534-41. PubMed ID: 3046887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Community-acquired lower respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors.
    Lode H
    Int J Clin Pract Suppl; 2002 Mar; (125):10-17; discussion 37-9. PubMed ID: 12014852
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experience with ampicillin/sulbactam in severe infections.
    Kanra G
    J Int Med Res; 2002; 30 Suppl 1():20A-30A. PubMed ID: 11921491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
    Campoli-Richards DM; Brogden RN
    Drugs; 1987 Jun; 33(6):577-609. PubMed ID: 3038500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections.
    Lode H
    Int J Antimicrob Agents; 2001 Sep; 18(3):199-209. PubMed ID: 11673031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ampicillin/sulbactam: current status in severe bacterial infections.
    Rafailidis PI; Ioannidou EN; Falagas ME
    Drugs; 2007; 67(13):1829-49. PubMed ID: 17722953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beta-lactam/beta-lactamase inhibitor combinations in empiric management of pediatric infections.
    Adam D
    J Int Med Res; 2002; 30 Suppl 1():10A-19A. PubMed ID: 11921490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beta-lactamases in clinical isolates. Spectrum implications of sulbactam/ampicillin.
    Acar JF; Gutmann L; Kitzis MD
    Drugs; 1988; 35 Suppl 7():12-6. PubMed ID: 3065051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sulbactam/ampicillin in the treatment of lower respiratory infections.
    Castellano MA
    Drugs; 1988; 35 Suppl 7():53-6. PubMed ID: 3065054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical pharmacology of antibiotics. Sulbactam/ampicillin.
    Salamone FR
    Infect Control Hosp Epidemiol; 1988 Jul; 9(7):323-7. PubMed ID: 3042857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.